hlaAllele	source	entryDate	sourceEvent	sourceUrls	nctId	title	acronym	genderCriterium	countriesAndCities	hospitalsPerCity	treatment	treatmentApproachesDrugClass	treatmentApproachesTherapy	applicableCancerType	applicableDoid	blacklistCancerTypes	efficacyDescription	efficacyDescriptionYear	evidenceLevel	evidenceLevelDetails	direction	evidenceUrls
A*02	CKB_TRIAL	1970-01-01	A*02	http	NCT1	study1	study1	female	Netherlands(Utrecht;Groningen)	Utrecht(UMCU),Groningen(UMCG)	Nivolumab			Skin melanoma	X	Hematologic cancer;2531		2024	A	GUIDELINE	RESPONSIVE	http
A*02	CKB_EVIDENCE	2021-02-03	A*02	http							Nivolumab			All cancer types	X	Hematologic cancer;2531	efficacy evidence	2024	A	GUIDELINE	RESPONSIVE	http
